Samir K. Gupta - Concepedia

Author

Samir K. Gupta

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Gupta, S.K., Gupta, Samir, Koletar, Susan L., M. Affrime, Rockstroh, J.K., S Gupta, S K Gupta, S. GUPTA, S. Gupta, S. K. Gupta

284

Publications

8.2K

Citations

H-Index

181

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Duke Medical Center Harvard University Case Western Reserve University

About

Samir K. Gupta is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pharmacology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	62	4K
2	Health Sciences	7	7	143
3	Humanities	2	2	29
4	Language Studies	1	1	16
5	Natural Sciences	1	1	46

Samir K. Gupta

124

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Samir K. Gupta, Joseph A. Eustace, Jonathan Winston, Clinical Infectious Diseases HypertensionImmunodeficienciesRenal PathologyImmunologyRenal Inflammation	2005	583
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection Lynda A. Szczech, Samir K. Gupta, Ramez Habash, Kidney International GlomerulonephritisHemodialysisUrologyRenal DiseasesRenal Function	2004	341
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders Christoph Sarrazin, Frank Wagner, Nicole Forestier, Gastroenterology HepatologyViral HepatitisImmunologyAntiviral Drug DevelopmentHepatitis	2007	311
Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America Gregory M. Lucas, Michael J. Ross, Peter G. Stock, Clinical Infectious Diseases	2014	304
Remifentanil Pharmacokinetics in Obese versus Lean Patients Talmage D. Egan, Bernou Huizinga, Samir K. Gupta, Anesthesiology	1998	275
A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C Paul Glue, Régine Rouzier‐Panis, C Raffanel, Hepatology	2000	248
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment Anton Pozniak, José Ramón Arribas, Joseph Gathe, JAIDS Journal of Acquired Immune Deficiency Syndromes	2015	184
Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System Samir K. Gupta AIDS Patient Care and STDs Drug SafetyThrombosisReporting BiasesTenofovir-associated Fanconi SyndromeClinical Epidemiology	2008	178
Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C J. Frank Jen, Paul Glue, Samir K. Gupta, Therapeutic Drug Monitoring Population PharmacokineticSerum CreatinineHepatologyHepatitis CViral Hepatitis	2000	169

Page 1